Citation Impact
Citing Papers
Crippling life support for SARS-CoV-2 and other viruses through synthetic lethality
2020 StandoutNobel
Colorectal cancer statistics, 2020
2020 Standout
Infrared molecular fingerprinting of blood-based liquid biopsies for the detection of cancer
2021 StandoutNobel
Colorectal cancer statistics, 2023
2023 Standout
Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again
2018 StandoutNobel
Breast cancer
2019 Standout
Breast-cancer detection using blood-based infrared molecular fingerprints
2021 StandoutNobel
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2024 Standout
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
2019 Standout
A view on drug resistance in cancer
2019 StandoutNature
From tumour heterogeneity to advances in precision treatment of colorectal cancer
2016
Microsatellite Instability in Colorectal Cancer
2010 Standout
Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer
2017
Integrating liquid biopsies into the management of cancer
2017
Right Versus Left Colon Cancer Biology: Integrating the Consensus Molecular Subtypes
2017
Liquid Biopsies, What We Do Not Know (Yet)
2017
Current and future perspectives of liquid biopsies in genomics-driven oncology
2018 Standout
Delivery technologies for cancer immunotherapy
2019 Standout
Colorectal cancer
2019 Standout
Synthetic lethality as an engine for cancer drug target discovery
2019
Pyroptosis: mechanisms and diseases
2021 Standout
Liquid biopsy
2015
Histology-agnostic drug development — considering issues beyond the tissue
2020
First FDA Approval Agnostic of Cancer Site — When a Biomarker Defines the Indication
2017
Liquid biopsies come of age: towards implementation of circulating tumour DNA
2017 Standout
Current and future biomarkers in colorectal cancer
2017
Regulation and Function of the PD-L1 Checkpoint
2018 Standout
Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis
2015
Current understanding of the human microbiome
2018 Standout
The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives
2020 Standout
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
2017 Standout
Untying the gordion knot of targeting MET in cancer
2018
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
2018 Standout
Differences Regarding the Molecular Features and Gut Microbiota Between Right and Left Colon Cancer
2018
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
Tumour heterogeneity and resistance to cancer therapies
2017 Standout
Fusobacterium nucleatum — symbiont, opportunist and oncobacterium
2018 Standout
Biomarker-driven and molecular targeted therapies for colorectal cancers
2017
Demographic trends in the incidence of young-onset colorectal cancer: a population-based study
2020
Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study
2019
Bacterial Biofilm and its Role in the Pathogenesis of Disease
2020 Standout
Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer
2019
Methylation analysis of Gasdermin E shows great promise as a biomarker for colorectal cancer
2019
Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer
2015
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
2018 StandoutNobel
Advances in Cancer Immunotherapy in Solid Tumors
2016
Artificial intelligence in cancer imaging: Clinical challenges and applications
2019 Standout
The Chemistry of Reactive Oxygen Species (ROS) Revisited: Outlining Their Role in Biological Macromolecules (DNA, Lipids and Proteins) and Induced Pathologies
2021 Standout
Clinical and molecular characterization of early‐onset colorectal cancer
2019
Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy
2018
Works of Van K. Morris being referenced
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancer
2015
Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes
2017
Association between KRAS mutation and lung metastasis in advanced colorectal cancer
2014
Progression-Free Survival Remains Poor Over Sequential Lines of Systemic Therapy in Patients With BRAF-Mutated Colorectal Cancer
2014
Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer
2016
Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment
2015
MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon
2016
Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406).
2017
Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin
2016
Phase Ib study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated metastatic colorectal cancer and advanced cancers.
2015
NCI9673: A multi-institutional eETCTN phase II study of nivolumab in refractory metastatic squamous cell carcinoma of the anal canal (SCCA).
2016
Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406).
2017
Phase 1B study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated advanced cancers and metastatic colorectal cancer.
2014
Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)
2020